Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.58 USD
Change Today -0.07 / -0.81%
Volume 2.4M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Key Developments

Novavax, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:00 AM

Novavax, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.

Novavax Seeks Acquisitions

Novavax, Inc. (NasdaqGS:NVAX) intends to use the proceeds for process development expenditures and capital expenditures, as well as acquisitions and other strategic purposes.

Novavax, Inc. Appoints Brian Rosen as Vice President, Government Affairs and Policy

Novavax, Inc. announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates. Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide.

Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM

Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Russell P Wilson, Senior VP, Business Development.

Novavax, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Novavax, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $6,724,000 compared to $8,748,000 a year ago. Loss from operations was $31,664,000 compared to $14,253,000 a year ago. Loss from operations before income tax expense was $31,546,000 compared to $14,051,000 a year ago. Net loss was $31,546,000 compared to $14,054,000 a year ago. Basic and diluted net loss per share was $0.13 compared to $0.07 a year ago. The increase in net loss is primarily the result of increased R&D expenses related to the successful RSV F vaccine program and the initiation of 3 RSV clinical trials in the third and fourth quarter of 2014. The 23% decrease in revenue was primarily related to revenues recognized under past agreement for the fourth quarter of 2013 related to the initiation of the Phase II RSV trial in women of childbearing age. For the full year, the company reported revenue of $30,659,000 compared to $20,915,000 a year ago. Loss from operations was $83,691,000 compared to $52,434,000 a year ago. Loss from operations before income tax expense was $82,947,000 compared to $51,958,000 a year ago. Net loss was $82,947,000 compared to $51,983,000 a year ago. Basic and diluted net loss per share was $0.37 compared to $0.31 a year ago. Net cash used in operating activities was $67.0 million, compared to $45.4 million for 2013. The increase in full year revenue results from the 2014 Phase I/II clinical trial of the H7N9 pandemic vaccine candidate and activities related to the preparation and initiation of the Phase II clinical trial of the quadrivalent seasonal influenza vaccine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $8.58 USD -0.07

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $36.00 USD -0.39
Advaxis Inc $23.34 USD -0.27
Dynavax Technologies Corp $23.31 USD -0.38
Inovio Pharmaceuticals Inc $10.35 USD -0.25
ZIOPHARM Oncology Inc $10.81 USD -0.395
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.8x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 69.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.